NO330491B1 - Rekombinant polynukleotid som koder for et polypeptid, eller antigent fragment derav, som indusere en immunrespons som er spesifikk for gruppe B streptococcus, vektor omfattende polynukleotidet, vertscelle transfektert med vektoren, fremgangsmate for fremstilling av polypeptidet, isolert polypeptid, vaksinesammensetning som omfatter polypeptidet,anvendelse av polypeptid ifolge oppfinnelsen for fremstilling av en vaksinesammensetning, isolert antistoff, eller antigenbindende fragment derav, som spesifikt binder til polypeptidet, fremgangsmate for pavisning av gruppe B Streptococcus i en biologisk prove, fremgangsmate for pavisning av et antistoff som spesifikt binder til polypeptidet. - Google Patents
Rekombinant polynukleotid som koder for et polypeptid, eller antigent fragment derav, som indusere en immunrespons som er spesifikk for gruppe B streptococcus, vektor omfattende polynukleotidet, vertscelle transfektert med vektoren, fremgangsmate for fremstilling av polypeptidet, isolert polypeptid, vaksinesammensetning som omfatter polypeptidet,anvendelse av polypeptid ifolge oppfinnelsen for fremstilling av en vaksinesammensetning, isolert antistoff, eller antigenbindende fragment derav, som spesifikt binder til polypeptidet, fremgangsmate for pavisning av gruppe B Streptococcus i en biologisk prove, fremgangsmate for pavisning av et antistoff som spesifikt binder til polypeptidet. Download PDFInfo
- Publication number
- NO330491B1 NO330491B1 NO20004161A NO20004161A NO330491B1 NO 330491 B1 NO330491 B1 NO 330491B1 NO 20004161 A NO20004161 A NO 20004161A NO 20004161 A NO20004161 A NO 20004161A NO 330491 B1 NO330491 B1 NO 330491B1
- Authority
- NO
- Norway
- Prior art keywords
- polypeptide
- seq
- amino acid
- antibody
- acid sequence
- Prior art date
Links
- 241000193990 Streptococcus sp. 'group B' Species 0.000 title claims description 152
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 106
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 106
- 229920001184 polypeptide Polymers 0.000 title claims description 105
- 239000012634 fragment Substances 0.000 title claims description 47
- 108091033319 polynucleotide Proteins 0.000 title claims description 38
- 102000040430 polynucleotide Human genes 0.000 title claims description 38
- 239000002157 polynucleotide Substances 0.000 title claims description 38
- 239000000203 mixture Substances 0.000 title claims description 31
- 108091007433 antigens Proteins 0.000 title claims description 29
- 102000036639 antigens Human genes 0.000 title claims description 29
- 239000000427 antigen Substances 0.000 title claims description 28
- 239000013598 vector Substances 0.000 title claims description 27
- 230000000890 antigenic effect Effects 0.000 title claims description 20
- 229960005486 vaccine Drugs 0.000 title claims description 19
- 230000028993 immune response Effects 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 8
- -1 isolated antibody Substances 0.000 title description 3
- 230000001939 inductive effect Effects 0.000 title description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 38
- 210000002966 serum Anatomy 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010061372 Streptococcal infection Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101710117545 C protein Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 241000193985 Streptococcus agalactiae Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 101150023497 mcrA gene Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
- KLYNHVIJEHPQTQ-UHFFFAOYSA-N 2-methylpropyl ethanedithioate Chemical compound CC(C)CSC(C)=S KLYNHVIJEHPQTQ-UHFFFAOYSA-N 0.000 description 1
- 229910017081 AlNH4(SO4)2 Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710150468 C protein alpha-antigen Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000006816 Neonatal Sepsis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000702208 Shigella phage SfX Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229910001679 gibbsite Inorganic materials 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 101150022503 phoR gene Proteins 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 101150057627 trxB gene Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7542598P | 1998-02-20 | 1998-02-20 | |
| PCT/CA1999/000114 WO1999042588A2 (en) | 1998-02-20 | 1999-02-17 | Group b streptococcus antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20004161D0 NO20004161D0 (no) | 2000-08-18 |
| NO20004161L NO20004161L (no) | 2000-10-19 |
| NO330491B1 true NO330491B1 (no) | 2011-05-02 |
Family
ID=22125658
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004161A NO330491B1 (no) | 1998-02-20 | 2000-08-18 | Rekombinant polynukleotid som koder for et polypeptid, eller antigent fragment derav, som indusere en immunrespons som er spesifikk for gruppe B streptococcus, vektor omfattende polynukleotidet, vertscelle transfektert med vektoren, fremgangsmate for fremstilling av polypeptidet, isolert polypeptid, vaksinesammensetning som omfatter polypeptidet,anvendelse av polypeptid ifolge oppfinnelsen for fremstilling av en vaksinesammensetning, isolert antistoff, eller antigenbindende fragment derav, som spesifikt binder til polypeptidet, fremgangsmate for pavisning av gruppe B Streptococcus i en biologisk prove, fremgangsmate for pavisning av et antistoff som spesifikt binder til polypeptidet. |
| NO20101682A NO20101682L (no) | 1998-02-20 | 2010-11-30 | Gruppe B streptococcus antigener |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20101682A NO20101682L (no) | 1998-02-20 | 2010-11-30 | Gruppe B streptococcus antigener |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20030031682A1 (enExample) |
| EP (3) | EP1757697A3 (enExample) |
| JP (2) | JP4637350B2 (enExample) |
| KR (1) | KR100771148B1 (enExample) |
| CN (2) | CN1268745C (enExample) |
| AP (1) | AP2000001886A0 (enExample) |
| AT (1) | ATE347600T1 (enExample) |
| AU (1) | AU2505999A (enExample) |
| CA (1) | CA2321106C (enExample) |
| CZ (1) | CZ301056B6 (enExample) |
| DE (1) | DE69934299T2 (enExample) |
| EA (1) | EA200000860A1 (enExample) |
| ES (2) | ES2278436T3 (enExample) |
| HU (1) | HU228497B1 (enExample) |
| ID (1) | ID27482A (enExample) |
| IL (3) | IL137921A0 (enExample) |
| NO (2) | NO330491B1 (enExample) |
| NZ (1) | NZ529854A (enExample) |
| OA (1) | OA11686A (enExample) |
| TR (1) | TR200002437T2 (enExample) |
| WO (1) | WO1999042588A2 (enExample) |
| ZA (1) | ZA991325B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2000001886A0 (en) * | 1998-02-20 | 2000-09-30 | Iaf Biochem Int | Group B streptococcus antigens. |
| US7098182B2 (en) | 1998-07-27 | 2006-08-29 | Microbial Technics Limited | Nucleic acids and proteins from group B streptococcus |
| WO2000006736A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Nucleic acids and proteins from group b streptococcus |
| CN101066447A (zh) | 1998-12-22 | 2007-11-07 | 微科学有限公司 | 基因和蛋白质,及它们的用途 |
| GB0105922D0 (en) * | 2001-03-09 | 2001-04-25 | Microscience Ltd | Genes and proteins, and their use |
| US6890539B2 (en) | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| CA2382795A1 (en) * | 1999-08-25 | 2001-03-01 | Medimmune, Inc. | Homologs of a pneumococcal protein and fragments for vaccines |
| US6833356B1 (en) | 1999-08-25 | 2004-12-21 | Medimmune, Inc. | Pneumococcal protein homologs and fragments for vaccines |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| US6866855B2 (en) | 2000-06-12 | 2005-03-15 | University Of Saskatchewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| DE60136356D1 (de) | 2000-06-12 | 2008-12-11 | Univ Saskatchewan | Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik |
| ES2273861T3 (es) * | 2000-06-12 | 2007-05-16 | University Of Saskatchewan | Inmunizacion de ganado vacuno lechero con proteina gapc frente a infecciones por streptococcus. |
| EP1734050A3 (en) * | 2000-06-12 | 2012-12-05 | University Of Saskatchewan | Immunization of dairy cattle with GapC protein against streptococcus infection |
| US7335368B2 (en) | 2000-10-13 | 2008-02-26 | Id Biomedical Corporation | BVH-A2 and BVH-A3 antigens of group B Streptococcus |
| ES2330083T3 (es) | 2000-10-27 | 2009-12-04 | Novartis Vaccines And Diagnostics S.R.L. | Acidos nucleicos y proteinas de estreptococos de los grupos a y b. |
| JP4080876B2 (ja) * | 2000-12-21 | 2008-04-23 | アイディー バイオメディカル コーポレイション | ストレプトコッカス・ピオゲネス抗原及び対応するｄｎａフラグメント |
| FR2824074A1 (fr) * | 2001-04-26 | 2002-10-31 | Pasteur Institut | Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques |
| ATE543906T1 (de) * | 2002-02-11 | 2012-02-15 | Id Biomedical Corp | Antigen von streptococcus aus der b-gruppe |
| GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
| US8945589B2 (en) | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| CA2575548A1 (en) | 2004-07-29 | 2006-07-27 | John L. Telford | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| EP1807446A2 (en) | 2004-10-08 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic and therapeutic compositions for streptococcus pyogenes |
| EP1845944A4 (en) * | 2005-02-08 | 2011-07-27 | Id Biomedical Corp Of Quebec C O B As Glaxosmithkline Biolog North America | PHARMACEUTICAL COMPOSITIONS |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| JP5653215B2 (ja) | 2007-09-12 | 2015-01-14 | ノバルティス アーゲー | Ｇａｓ５７変異体抗原およびｇａｓ５７抗体 |
| EP2537857B1 (en) | 2007-12-21 | 2017-01-18 | GlaxoSmithKline Biologicals SA | Mutant forms of streptolysin O |
| CN102304185A (zh) * | 2011-09-02 | 2012-01-04 | 黑龙江八一农垦大学 | 预防奶牛乳房炎的融合蛋白sip-trap及制备方法和应用 |
| EP2949340A1 (en) * | 2014-05-30 | 2015-12-02 | IDT Biologika GmbH | Vaccine composition against Streptococcus suis infection |
| CN115057944B (zh) * | 2022-06-24 | 2025-06-24 | 南京农业大学 | 一种针对所有gbs血清型的多表位亚单位疫苗 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
| US5472696A (en) * | 1988-02-26 | 1995-12-05 | Univ. Of Florida Research Foundation, Inc. | Antigen of group B streptococci |
| US5648241A (en) * | 1989-09-15 | 1997-07-15 | The General Hospital Corporation | Conjugate vaccine against group B streptococcus |
| US5679768A (en) * | 1991-02-15 | 1997-10-21 | Uab Research Foundation | Epitopic regions of pneumococcal surface protein A |
| US5225331A (en) * | 1991-04-25 | 1993-07-06 | National Research Council Of Canada | Immunoassay for detecting group b streptococcus |
| DE69432658T2 (de) * | 1993-03-19 | 2004-04-08 | Gunnar Lindahl | Rib-protein, ein oberflächenprotein welches immunität gegen viele streptococcus-stämme der gruppe b verleiht, reinigungsverfahren für das rib-protein, testsatz und pharmazeutische zusammenstellung (arznei) |
| US5595740A (en) * | 1994-05-16 | 1997-01-21 | University Of Florida | Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens |
| CN1142229A (zh) * | 1994-11-01 | 1997-02-05 | 麒麟麦酒株式会社 | 形成粘蛋白糖链的肽序列和修饰蛋白质使与粘蛋白糖链相连的方法 |
| US6420135B1 (en) * | 1996-10-31 | 2002-07-16 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| AP2000001886A0 (en) * | 1998-02-20 | 2000-09-30 | Iaf Biochem Int | Group B streptococcus antigens. |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| WO2000006736A2 (en) | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Nucleic acids and proteins from group b streptococcus |
| US6582706B1 (en) | 1998-12-21 | 2003-06-24 | Medimmune, Inc. | Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS |
| EA007409B1 (ru) | 1998-12-23 | 2006-10-27 | Шайе Биокем Инк. | Антигенные полипептиды стрептококков, способы их получения и применения |
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| GB9921125D0 (en) | 1999-09-07 | 1999-11-10 | Microbial Technics Limited | Proteins |
| ATE543906T1 (de) | 2002-02-11 | 2012-02-15 | Id Biomedical Corp | Antigen von streptococcus aus der b-gruppe |
-
1999
- 1999-02-17 AP APAP/P/2000/001886A patent/AP2000001886A0/en unknown
- 1999-02-17 CN CNB998052485A patent/CN1268745C/zh not_active Expired - Lifetime
- 1999-02-17 JP JP2000532528A patent/JP4637350B2/ja not_active Expired - Lifetime
- 1999-02-17 EP EP20060022306 patent/EP1757697A3/en not_active Withdrawn
- 1999-02-17 CZ CZ20003054A patent/CZ301056B6/cs not_active IP Right Cessation
- 1999-02-17 KR KR1020007009237A patent/KR100771148B1/ko not_active Expired - Lifetime
- 1999-02-17 EP EP99904646A patent/EP1054971B1/en not_active Expired - Lifetime
- 1999-02-17 AT AT99904646T patent/ATE347600T1/de not_active IP Right Cessation
- 1999-02-17 CN CNA2006100913640A patent/CN1944652A/zh active Pending
- 1999-02-17 ID IDW20001856A patent/ID27482A/id unknown
- 1999-02-17 CA CA2321106A patent/CA2321106C/en not_active Expired - Lifetime
- 1999-02-17 HU HU0102304A patent/HU228497B1/hu unknown
- 1999-02-17 ES ES99904646T patent/ES2278436T3/es not_active Expired - Lifetime
- 1999-02-17 EA EA200000860A patent/EA200000860A1/ru unknown
- 1999-02-17 TR TR2000/02437T patent/TR200002437T2/xx unknown
- 1999-02-17 IL IL13792199A patent/IL137921A0/xx active IP Right Grant
- 1999-02-17 EP EP10180962.2A patent/EP2280072B1/en not_active Expired - Lifetime
- 1999-02-17 ES ES10180962.2T patent/ES2540281T3/es not_active Expired - Lifetime
- 1999-02-17 AU AU25059/99A patent/AU2505999A/en not_active Abandoned
- 1999-02-17 OA OA1200000228A patent/OA11686A/en unknown
- 1999-02-17 WO PCT/CA1999/000114 patent/WO1999042588A2/en not_active Ceased
- 1999-02-17 DE DE69934299T patent/DE69934299T2/de not_active Expired - Lifetime
- 1999-02-18 ZA ZA9901325A patent/ZA991325B/xx unknown
- 1999-02-18 US US09/252,088 patent/US20030031682A1/en active Pending
-
2000
- 2000-08-17 IL IL137921A patent/IL137921A/en not_active IP Right Cessation
- 2000-08-18 NO NO20004161A patent/NO330491B1/no not_active IP Right Cessation
-
2003
- 2003-01-13 US US10/340,792 patent/US7914794B2/en not_active Expired - Lifetime
- 2003-11-28 NZ NZ529854A patent/NZ529854A/en not_active IP Right Cessation
-
2008
- 2008-03-09 IL IL190018A patent/IL190018A/en not_active IP Right Cessation
-
2009
- 2009-06-02 JP JP2009132976A patent/JP2009242403A/ja active Pending
-
2010
- 2010-11-30 NO NO20101682A patent/NO20101682L/no not_active Application Discontinuation
- 2010-12-28 US US12/980,172 patent/US8226953B2/en not_active Expired - Fee Related
-
2012
- 2012-07-16 US US13/550,363 patent/US8580262B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20101682L (no) | Gruppe B streptococcus antigener | |
| EP2261358B1 (en) | Novel streptococcus antigen | |
| EP2281891A2 (en) | Streptococcus antigens | |
| AU2001270381A1 (en) | Streptococcus antigens | |
| US7074415B2 (en) | Streptococcus antigens | |
| AU2007202175B2 (en) | Group B Streptococcus Antigens | |
| AU2007200130B2 (en) | Group B Streptococcus Antigens | |
| CA2424433A1 (en) | Bvh-a2 and bvh-a3 antigens of group b streptococcus | |
| HK1100752A (en) | Group b streptococcus antigens | |
| MXPA00008111A (en) | Group b streptococcus antigens | |
| AU2007207883A1 (en) | Streptococcus antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |